Market Research Logo

TNF Inhibitors - A Pipeline Analysis Report

TNF Inhibitors - A Pipeline Analysis Report

TNF Inhibitors: An insight

The TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global blockbuster drugs and have dominated the global pharmaceutical market landscape for many years. The report includes classification of the pipeline by type of molecules such monoclonal antibody, polyclonal antibody, recombinant fusion protein, and a small molecule.

Around 45% of TNF inhibitors in pipeline are being evaluated for the treatment of RA. According to the Centers for Disease Control and Prevention (CDC), around 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040.

Covered in this report

The report covers the present scenario and the growth prospects of the TNF inhibitors. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio's TNF Inhibitors - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.

Major companies

  • Pfizer
  • Boehringer Ingelheim
  • Novartis
  • Amgen
  • Mochida Pharmaceutical
  • Hanall
  • BioPharma
  • Key questions answered in this report
    • How will the market evolve during the forecast period?
    • What are the major parameters impacting the market?
    • What are the key market trends?
    • What are the challenges to market growth?
    • Who are the key companies in this market space?

    Press Release

    Technavio Announces the Publication of its Research Report - TNF Inhibitors - A Pipeline Analysis Report

    Technavio recognizes the following companies in the TNF inhibitors: Pfizer, Boehringer Ingelheim, Novartis, Amgen, Mochida Pharmaceutical, Hanall, and BioPharma.

    TNF is involved in a wide range of autoimmune and inflammatory disorders such as rheumatoid arthritis (RA), ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. Besides its biological importance, TNF is important in terms of commercial value as anti-TNF antibody medicines are one of the world’s best-selling medicines.

    For instance, adalimumab (anti-TNF antibody) is one of the top-selling medicines with global sales of over $10,000 million per year. The total annual sales of various anti-TNFs/anti-TNF receptor (TNFR) drugs are exceeding $25,000 million globally, thus making anti-TNFs as one of the most profitable drug classes. The importance of TNF inhibitors becomes much more relevant due to its use in the treatment of various health conditions.

    Most of the TNF inhibitors being evaluated currently in the pipeline are biologicals. Moreover, six of the top 10 best-selling pharmaceuticals are biologicals and nearly half of all clinical trials are conducted for injectable proteins related to antibodies. Due to its effective outcome in the treatment of autoimmune and inflammatory disorders, TNF inhibitors are considered as the physicians first choice of treatment globally for such devastating health conditions.

    Companies Mentioned

    Pfizer, Boehringer Ingelheim, Novartis, Amgen, Mochida Pharmaceutical, Hanall, and BioPharma.

    • Executive summary
    • Scope of the report
    • Research methodology
    • TNF inhibitor Insight
      • Introduction
        • Table An overview of pipeline molecules 2017
    • Pipeline landscape
      • Table Pipeline landscape
    • Pipeline molecules by vendors
      • Table Pipeline molecules by vendors 2017
    • Comparative analysis
      • Table Pipeline molecules in different developmental stages 2017
      • Table Pipeline molecules in different developmental stages 2017 (%)
      • Late-stage molecules (filed and Phase III)
        • Table Late-stage molecules by different vendors 2017
        • Table Overview: PF-06438179
        • Table Overview: BI 695501
        • Table Overview: GP2017
        • Table Overview: SB5
        • Table Overview: LBEC0101
        • Table Overview: TuNEX (etanercept)
        • Table Overview: BCD-057
        • Table Clinical trials description of BCD-057
        • Table Overview: CIMZIA
        • Table Clinical trials description for CIMZIA
        • Table Overview: PF-06410293
        • Table Overview: ABP 710
        • Table Overview: CHS-0214
        • Table Overview: IBI 303
        • Table Overview: LBAL
      • Mid-stage molecules (Phase II)
        • Table Overview: OPRX-106
        • Table Overview: ATN-103
      • Early-stage molecules (Phase I and IND)
        • Table Overview: TNF Oral
        • Table Overview: AVX 470
        • Table Overview: T0001
        • Table Overview: HL036
      • Pre-clinical molecules
        • Table Overview: Adalimumab
      • Status unknown molecules
        • Table Overview: BX2922
      • Discontinued products
        • Table Overview: AZD9773
      • Dormant products
        • Table Overview: Adalimumab biosimilar
        • Table Overview: Etanercept biosimilar
    • Indication analysis
      • Table Analysis of pipeline molecules by indication 2017
      • Table Overview of top three indications 2017
    • Marketed drugs
      • Top selling drugs
        • Table Overview: HUMIRA
        • Table Overview: Remicade
        • Table Overview: CIMZIA
        • Table Overview: Enbrel
    • Therapeutic assessment by therapy
      • Therapeutic assessment based on therapy
        • Table Assessment by monotherapy products 2017
    • Therapeutic assessment by RoA
      • Therapeutic assessment based on RoA
        • Table Assessment by RoA 2017
    • Therapeutic assessment by molecule type
      • Therapeutic assessment based on molecule type
        • Table Assessment by molecule type (number of molecules) 2017
        • Table Assessment by molecule type (%) 2017
    • Key companies
      • Active companies: Category and parameters
        • Table Active companies: Category and parameters 2017
        • Table Segmentation of companies 2017
        • Table Overview: Ablynx 2017
        • Table Overview: Amgen 2016
        • Table Overview: Avaxia Biologics 2016
        • Table Overview: BIOCAD 2016
        • Table Overview: BioXpress Therapeutics 2017
        • Table Overview: Coherus Biosciences 2017
        • Table Overview: Dermira 2016
        • Table Overview: Hanall BioPharma 2017
        • Table Overview: Innovent Biologics
        • Table Overview: Levolta Pharmaceuticals 2016
        • Table Overview: Mochida Pharmaceutical 2017
        • Table Overview: Mycenax Biotech 2017
        • Table Overview: Novartis 2016
        • Table Overview: Pfizer 2016
        • Table Overview: Protalix 2016
        • Table Overview: Samsung Bioepis 2016
        • Table Overview: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical 2016
    • Appendix
      • List of abbreviations
    • Explore Technavio

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report